Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903030 · ClinicalTrials.gov registry record · Early Phase 1
Probiotics for Quality of Life in Autism Spectrum Disorders
A Early Phase 1 study of Anxiety and Autism Spectrum Disorders, sponsored by Ohio State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02903030: Completed Early Phase 1 study of Anxiety and Autism Spectrum Disorders, sponsored by Ohio State University.
NCT02903030 is a Early Phase 1 study of Anxiety and Autism Spectrum Disorders that has completed, run by Ohio State University. The registered enrollment target is 13 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02903030, a Early Phase 1 study of Anxiety and Autism Spectrum Disorders, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized pilot trial of a probiotic for quality of life in autism spectrum disorder (ASD), targeting gastrointestinal (GI) symptoms.
Primary Outcome
A 74-item survey with 14 scales. Report forms for specific age ranges assess the parent's perception of the child's GI function and/or symptoms during the last month on a 5-point scale from 0 (never a problem) to 4 (almost always a problem). Items are reverse-scored and transformed to a 0-100 scale so lower scores reflect worse GI dysfunction. Response choices are in Likert-scale format ranging from 0 to 4 (0=Never, 1=Almost Never, 2=Sometimes, 3=Often, 4=Almost Always).
Conditions Studied
Interventions
- DRUG Maltose (placebo)
- DRUG Visbiome Extra Strength
Study Locations (1)
Ohio
- Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-12-01 |
| Phase | Early Phase 1 |
What the finished NCT02903030 record still lists
NCT02903030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Maltose (placebo) is the first listed.
NCT02903030 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02903030 about?
NCT02903030 is a clinical study titled "Probiotics for Quality of Life in Autism Spectrum Disorders". A randomized pilot trial of a probiotic for quality of life in autism spectrum disorder (ASD), targeting gastrointestinal (GI) symptoms.
What is the current status of trial NCT02903030?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2016-08. Estimated completion is 2017-12-01.
What conditions does trial NCT02903030 study?
This clinical trial studies the following conditions: Anxiety, Autism Spectrum Disorders.
What interventions are being tested in trial NCT02903030?
The interventions under investigation include: Maltose (placebo) (DRUG), Visbiome Extra Strength (DRUG).
Who is sponsoring clinical trial NCT02903030?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02903030 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02903030's enrollment target sits among peer trials
13 351st of 364 higher than 14 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep, Dreaming, and Virtual Reality for Mental Health
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia